Astrazeneca’s Stock is Outperforming the Company
Pharmaceutical company AstraZeneca (NYSE: AZN) is in a unique situation currently. The stock is performing much better than the company. What do I mean by that? The stock price is growing much faster than the company’s earnings or sales.
If we look at the daily chart, you can see that the stock price has been trending higher over the last nine months. The upward trend actually goes back to the end of 2016, but I wanted to show you the trend channel that has formed on the stock over the last nine months.
The stock has just bounced off of the lower rail of the channel and the stochastic readings have just made a bullish crossover and look to be moving out of oversold territory. The last time we saw this same scenario was in mid-October and the stock jumped from below $37 to over $41.50.
If you look back over the last two years, the stock has gained 57.3% while the S&P is up 17.5% over this same time period. If we look at Investor’s Business Daily’s relative strength rating, the stock scores a 90. This means that Astrazeneca’s stock has appreciated better than 90% of all publicly traded stocks over the past year.
In the meantime, the company has seen earnings decline by an average of 5% per year over the last three years and sales have declined at a 5% rate over the same period. In the most recent quarterly report, earnings dropped by 37% and sales dropped by 14%.
This is a unique scenario and you wouldn’t expect it to go on very long. Either the fundamentals will catch up with the stock price, or the stock price will start falling to catch up to the earnings and sales on the downside.
AZN in downward trend: price dove below 50-day moving average on June 20, 2025
AZN moved below its 50-day moving average on June 20, 2025 date and that indicates a change from an upward trend to a downward trend. In of 57 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are .
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for AZN moved out of overbought territory on June 13, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 35 similar instances where the indicator moved out of overbought territory. In of the 35 cases, the stock moved lower in the following days. This puts the odds of a move lower at .
The Momentum Indicator moved below the 0 level on June 17, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on AZN as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .
The Moving Average Convergence Divergence Histogram (MACD) for AZN turned negative on June 17, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 42 similar instances when the indicator turned negative. In of the 42 cases the stock turned lower in the days that followed. This puts the odds of success at .
Following a 3-day decline, the stock is projected to fall further. Considering past instances where AZN declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
AZN broke above its upper Bollinger Band on June 12, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 1 day, which means it's wise to expect a price bounce in the near future.
The 10-day moving average for AZN crossed bullishly above the 50-day moving average on May 30, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where AZN advanced for three days, in of 345 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Aroon Indicator entered an Uptrend today. In of 275 cases where AZN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.325) is normal, around the industry mean (5.632). P/E Ratio (35.297) is within average values for comparable stocks, (48.974). Projected Growth (PEG Ratio) (0.870) is also within normal values, averaging (3.004). Dividend Yield (0.022) settles around the average of (0.161) among similar stocks. P/S Ratio (4.585) is also within normal values, averaging (3.643).
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 78, placing this stock slightly better than average.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. AZN’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a manufacturer of pharmaceutical products
Industry PharmaceuticalsMajor
Advertisement